Amelioration of ovalbumin-induced allergic airway disease following der p 1 peptide immunotherapy is not associated with induction of IL-35

Mucosal Immunology

Volumn 7, Issue 2, 2014, Pages 379-390

  Moldaver, D M ^a   Bharhani, M S ^a   Wattie, J N ^a   Ellis, R ^a   Neighbour, H ^a   Lloyd, C M ^b   Inman, M D ^a   Larche M ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DER P 1 PEPTIDE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 35; OVALBUMIN; PEPTIDE DERIVATIVE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL HYPERPLASIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DERMATOPHAGOIDES; DRUG EFFECT; EOSINOPHILIA; FEMALE; GOBLET CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT ALLERGY; T LYMPHOCYTE; TH2 CELL;

ALLERGENS; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; ARTHROPOD PROTEINS; CYSTEINE ENDOPEPTIDASES; DESENSITIZATION, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; INTERLEUKIN-10; INTERLEUKIN-17; INTERLEUKIN-5; INTERLEUKINS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MICE; OVALBUMIN; PEPTIDE FRAGMENTS; PNEUMONIA; RESPIRATORY HYPERSENSITIVITY;

EID: 84895162089     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2013.56     Document Type: Article

References (63)

1. O+Mahony, L., Akdis, M., Crameri, R. & Akdis, C.A. Novel immunotherapeutic approaches for allergy and asthma. Autoimmunity 43, 493-503 (2010).
2. Crameri, R. Allergy vaccines: Dreams and reality. Expert Rev. Vaccines 6, 991-999 (2007).
3. Lockey, R.F., Nicoara-Kasti, G.L., Theodoropoulos, D.S. & Bukantz, S.C. Systemic reactions and fatalities associated with allergen immunotherapy. Ann. Allergy Asthma Immunol. 87 (1 Suppl 1), 47-55 (2001).
4. Nettis, E., Giordano, D., Pannofino, A., Ferrannini, A. & Tursi, A. Safety of inhalant allergen immunotherapy with mass units-standardized extracts. Clin. Exp. Allergy 32, 1745-1749 (2002).
5. Campbell, J.D. et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J. Exp. Med. 206, 1535-1547 (2009).
6. Moldaver, D. & Larche, M. Immunotherapy with peptides. Allergy 66, 784-791 (2011).
7. Oldfield, W.L., Kay, A.B. & Larche, M. Allergen-derived T cell peptideinduced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J. Immunol. 167, 1734-1739 (2001).
8. Massey, E.J., Sundstedt, A., Day,M.J., Corfield, G., Anderton, S. & Wraith, D.C. Intranasal peptide-induced peripheral tolerance: The role of IL-10 in regulatory T cell function within the context of experimental autoimmune encephalomyelitis. Vet. Immunol. Immunopathol. 87, 357-372 (2002).
9. Hoyne, G.F., O+Hehir, R.E., Wraith, D.C., Thomas, W.R. & Lamb, J.R. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J. Exp. Med. 178, 1783-1788 (1993).
10. Verhoef, A., Alexander, C., Kay, A.B. & Larche, M.T. Cell epitope immunotherapy induces a CD4(+) T cell population with regulatory activity. PLoS Med. 2, e78 (2005).
11. Van Hove, C.L., Maes, T., Joos, G.F. & Tournoy, K.G. Prolonged inhaled allergen exposure can induce persistent tolerance. Am. J. Respir. Cell Mol. Biol. 36, 573-584 (2007).
12. Astori, M., von Garnier,C., Kettner, A., Dufour, N., Corradin, G. & Spertini, F. Inducing tolerance by intranasal administration of long peptides in naive and primed CBA/J mice. J. Immunol. 165, 3497-3505 (2000).
13. Briner, T.J., Kuo, M.C., Keating, K.M., Rogers, B.L. & Greenstein, J.L. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc. Natl. Acad. Sci. USA 90, 7608-7612 (1993).
14. Gaur, A., Wiers, B., Liu, A., Rothbard, J. & Fathman, C.G. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptideinduced anergy. Science 258, 1491-1494 (1992).
15. Karin, N., Mitchell, D.J., Brocke, S., Ling, N. & Steinman, L. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of amyelin basic protein epitope: Tcell receptor antagonismand reduction of interferon gamma and tumor necrosis factor alpha production. J. Exp. Med. 180, 2227-2237 (1994).
16. van, E.W., Van Der Zee, R., Taams, L.S., Prakken, A.B., van, R.J. & Wauben, M.H. Heat-shock protein T-cell epitopes trigger a spreading regulatory control in a diversified arthritogenic T-cell response. Immunol. Rev. 164, 169-174 (1998).
17. Wauben, M.H., Boog, C.J., Van Der Zee, R., Joosten, I., Schlief, A. & van, E.W. Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: More than blocking alone. J. Exp. Med. 176, 667-677 (1992).
18. Burkhart, C., Liu, G.Y., Anderton, S.M.,Metzler, B. & Wraith, D.C. Peptideinduced Tcell regulation of experimental autoimmune encephalomyelitis: A role for IL-10. Int. Immunol. 11, 1625-1634 (1999).
19. Metzler, B. & Wraith, D.C. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: Influence of MHC binding affinity. Int. Immunol. 5, 1159-1165 (1993).
20. Prakken, B. et al. Nasal administration of arthritis-related Tcell epitopes of heat shock protein 60 as a promising way for immunotherapy in chronic arthritis. Biotherapy 10, 205-211 (1998).
21. Norman, P.S. et al. Treatment of cat allergy with T-cell reactive peptides. Am. J. Respir. Crit. Care Med. 154 (6 Pt 1), 1623-1628 (1996).
22. Pene, J. et al. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J. Allergy Clin. Immunol. 102 (4 Pt 1), 571-578 (1998).
23. Maguire, P., Nicodemus, C., Robinson, D., Aaronson, D. & Umetsu, D.T. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin. Immunol. 93, 222-231 (1999).
24. Simons, F.E., Imada, M., Li, Y., Watson, W.T. & HayGlass, K.T. Fel d 1 peptides: Effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int. Immunol. 8, 1937-1945 (1996).
25. Muller, U. et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. 101 (6 Pt 1), 747-754 (1998).
26. Oldfield, W.L., Larche, M. & Kay, A.B. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: A randomised controlled trial. Lancet 360, 47-53 (2002).
27. Worm, M. et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J. Allergy Clin. Immunol. 127, 89-97 (2011).
28. Fellrath, J.M. et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: Results of a phase I trial. J. Allergy Clin. Immunol. 111, 854-861 (2003).
29. Warren, K.G., Catz, I. & Wucherpfennig, K.W. Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. J. Neurol. Sci. 152, 31-38 (1997).
30. Kappos, L. et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in relapsing MS Study Group. Nat. Med. 6, 1176-1182 (2000).
31. Bielekova, B. et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6, 1167-1175 (2000).
32. Koffeman, E.C. et al. Epitope-specific immunotherapy of rheumatoid arthritis: Clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with Tcell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum. 60, 3207-3216 (2009).
33. Prakken, B.J. et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 101, 4228-4233 (2004).
34. Thrower, S.L. et al. Proinsulin peptide immunotherapy in type 1 diabetes: Report of a first-in-man Phase I safety study. Clin. Exp. Immunol. 155, 156-165 (2009).
35. Larche, M. & Wraith, D.C. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. 11 (4 Suppl), S69-S76 (2005).
36. Patel, D. et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study. J. Allergy Clin. Immunol. 131, 103-109 (2013).
37. Walsh, P.T., Taylor, D.K. & Turka, L.A. Tregs and transplantation tolerance. J. Clin. Invest. 114, 1398-1403 (2004).
38. Graca, L., Chen, T.C., Le, M.A., Cobbold, S.P., Howie, D. &Waldmann, H. Dominant tolerance: Activation thresholds for peripheral generation of regulatory T cells. Trends Immunol. 26, 130-135 (2005).
39. Haley, K.J. & Drazen, J.M. Inflammation and airway function in asthma: What you see is not necessarilywhat you get. Am. J. Respir.Crit. Care Med. 157, 1-3 (1998).
40. Crimi, E., Spanevello, A., Neri, M., Ind, P.W., Rossi, G.A. & Brusasco, V. Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma. Am. J. Respir. Crit. Care Med. 157, 4-9 (1998).
41. Flood-Page, P.T., Menzies-Gow, A.N., Kay, A.B. & Robinson, D.S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. 167, 199-204 (2003).
42. Lemiere, C. et al. Airway inflammation assessed by invasive and noninvasive means in severe asthma: Eosinophilic and noneosinophilic phenotypes. J. Allergy Clin. Immunol. 118, 1033-1039 (2006).
43. McMillan, S.J., Bishop, B., Townsend,M.J., McKenzie, A.N. & Lloyd, C.M. The absence of interleukin 9 does not affect the development of allergeninduced pulmonary inflammation nor airway hyperreactivity. J. Exp. Med. 195, 51-57 (2002).
44. DiGiovanni, F.A., Ellis,R.,Wattie, J., Hirota, J.A., Southam, D.S.& Inman,M.D. Concurrent dual allergen exposure and its effects on airway hyperresponsiveness, inflammation and remodeling inmice. Dis.ModelMech. 2, 275-282 (2009).
45. Coyle, A.J. et al. Crucial role of the interleukin 1 receptor family member T1/ ST2 in T helper cell type 2-mediated lung mucosal immune responses. J. Exp. Med. 190, 895-902 (1999).
46. Schmitz, J. et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479-490 (2005).
47. Kearley, J., Buckland, K.F., Mathie, S.A. & Lloyd, C.M. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am. J. Respir. Crit. Care Med. 179, 772-781 (2009).
48. Hogan, S.P., Koskinen, A., Matthaei, K.I., Young, I.G. & Foster, P.S. Interleukin-5-producing CD4+ T cells play a pivotal role in aeroallergeninduced eosinophilia, bronchial hyperreactivity, and lung damage in mice. Am. J. Respir. Crit. Care Med. 157, 210-218 (1998).
49. Zhao, Y., Yang, J., Gao, Y.D. & Guo, W. Th17 immunity in patients with allergic asthma. Int. Arch. Allergy Immunol. 151, 297-307 (2010).
50. Wilson, R.H., Whitehead, G.S., Nakano, H., Free,M.E., Kolls, J.K. & Cook, D.N. Allergic sensitization through the airway primes Th17-dependent neutrophilia and airway hyperresponsiveness. Am. J. Respir. Crit. Care Med. 180, 720-730 (2009).
51. Hamelmann, E. et al. Requirement for CD8+ Tcells in the development of airway hyperresponsiveness in a marine model of airway sensitization. J. Exp. Med. 183, 1719-1729 (1996).
52. Isogai, S., Taha, R., Tamaoka, M., Yoshizawa, Y., Hamid, Q. & Martin, J.G. CD8+ alphabeta T cells can mediate late airway responses and airway eosinophilia in rats. J. Allergy Clin. Immunol. 114, 1345-1352 (2004).
53. Croft, M., Carter, L., Swain, S.L. & Dutton, R.W. Generation of polarized antigen-specific CD8 effector populations: Reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J. Exp. Med. 180, 1715-1728 (1994).
54. Azzawi,M. et al. Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am. Rev. Respir. Dis. 142 (6 Pt 1), 1407-1413 (1990).
55. Secrist, H., DeKruyff, R.H. & Umetsu, D.T. Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J. Exp. Med. 181, 1081-1089 (1995).
56. Akdis, C.A., Blesken, T., Akdis, M., Wuthrich, B. & Blaser, K. Role of interleukin 10 in specific immunotherapy. J. Clin. Invest. 102, 98-106 (1998).
57. Allan, S.E. et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int. Immunol. 19, 345-354 (2007).
58. Collison, L.W. et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450, 566-569 (2007).
59. Chaturvedi, V., Collison, L.W., Guy, C.S., Workman, C.J. & Vignali, D.A. Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J. Immunol. 186, 6661-6666 (2011).
60. Whitehead, G.S., Wilson, R.H., Nakano, K., Burch, L.H., Nakano, H. & Cook, D.N. IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. J. Allergy Clin. Immunol. 129, 207-215 (2012).
61. Singh, A. et al. Regulatory role of B cells in amurine model of allergic airway disease. J. Immunol. 180, 7318-7326 (2008).
62. Amu, S., Saunders, S.P., Kronenberg, M., Mangan, N.E., Atzberger, A. & Fallon, P.G. Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model. J. Allergy Clin. Immunol. 125, 1114-1124 (2010).
63. Hirota, J.A, Ellis, R & Inman, M.D. Regional differences in the pattern of airway remodeling following chronic allergen exposure inmice. Respir. Res. 21, 120 (2006).